Abstract
The transcription factor nuclear factor erythroid 2-like 2 (NEF2L2; NRF2) plays crucial roles in the defense system against electrophilic or oxidative stress by upregulating an array of genes encoding antioxidant proteins, electrophile/reactive oxygen species (ROS) detoxifying enzymes, and drug efflux transporters. In contrast to the protective roles in normal cells, the multifaceted role of NRF2 in tumor growth and progression, resistance to therapy and intratumoral stress, and metabolic adaptation is rapidly expanding, and the complex association of NRF2 with cancer signaling networks is being unveiled. In particular, the implication of NRF2 signaling in cancer stem cells (CSCs), a small population of tumor cells responsible for therapy resistance and tumor relapse, is emerging. Here, we described the dark side of NRF2 signaling in cancers discovered so far. A particular focus was put on the role of NRF2 in CSCs maintenance and therapy resistance, showing that low ROS levels and refractory drug response of CSCs are mediated by the activation of NRF2 signaling. A better understanding of the roles of the NRF2 pathway in CSCs will allow us to develop a novel therapeutic approach to control tumor relapse after therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Achuthan S, Santhoshkumar TR, Prabhakar J, Nair SA, Pillai MR (2011) Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J Biol Chem 286(43):37813–37829. https://doi.org/10.1074/jbc.M110.200675
Agyeman AS, Chaerkady R, Shaw PG, Davidson NE, Visvanathan K, Pandey A, Kensler TW (2012) Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res Treat 132(1):175–187. https://doi.org/10.1007/s10549-011-1536-9
Almazari I, Park JM, Park SA, Suh JY, Na HK, Cha YN, Surh YJ (2012) Guggulsterone induces heme oxygenase-1 expression through activation of Nrf2 in human mammary epithelial cells: PTEN as a putative target. Carcinogenesis 33(2):368–376. https://doi.org/10.1093/carcin/bgr259
Arfmann-Knübel S, Struck B, Genrich G, Helm O, Sipos B, Sebens S, Schäfer H (2015) The crosstalk between Nrf2 and TGF-β1 in the epithelial-mesenchymal transition of pancreatic duct epithelial cells. PLoS ONE 10(7):e0132978. https://doi.org/10.1371/journal.pone.0132978
Arlt A, Sebens S, Krebs S, Geismann C, Grossmann M, Kruse ML, Schreiber S, Schäfer H (2013) Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 32(40):4825–4835. https://doi.org/10.1038/onc.2012.493
Baines P, Visser JJEH (1983) Analysis and separation of murine bone marrow stem cells by H33342 fluorescence-activated cell sorting. Exp Hematol 11(8):701–708
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JNJN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756. https://doi.org/10.1038/nature05236
Batlle E, Clevers H (2017) Cancer stem cells revisited. Nat Med 23(10):1124–1134. https://doi.org/10.1038/nm.4409
Best SA, De Souza DP, Kersbergen A, Policheni AN, Dayalan S, Tull D, Rathi V, Gray DH, Ritchie ME, McConville MJ, Sutherland KD (2018) Synergy between the KEAP1/NRF2 and PI3K pathways drives non-small-cell lung cancer with an altered immune microenvironment. Cell Metab 27(4):935-943.e934. https://doi.org/10.1016/j.cmet.2018.02.006
Cai SJ, Liu Y, Han S, Yang C (2019) Brusatol, an NRF2 inhibitor for future cancer therapeutic. Cell Biosci 9:45. https://doi.org/10.1186/s13578-019-0309-8
Chang CW, Chen YS, Tsay YG, Han CL, Chen YJ, Yang CC, Hung KF, Lin CH, Huang TY, Kao SY, Lee TC, Lo JF (2018) ROS-independent ER stress-mediated NRF2 activation promotes warburg effect to maintain stemness-associated properties of cancer-initiating cells. Cell Death Dis 9(2):194. https://doi.org/10.1038/s41419-017-0250-x
Chaudhari P, Ye Z, Jang YY (2014) Roles of reactive oxygen species in the fate of stem cells. Antioxid Redox Signal 20(12):1881–1890. https://doi.org/10.1089/ars.2012.4963
Chen JS, Pardo FS, Wang-Rodriguez J, Chu TS, Lopez JP, Aguilera J, Altuna X, Weisman RA, Ongkeko WM (2006) EGFR regulates the side population in head and neck squamous cell carcinoma. Laryngoscope 116(3):401–406. https://doi.org/10.1097/01.mlg.0000195075.14093.fb
Chiou S-H, Wang M-L, Chou Y-T, Chen C-J, Hong C-F, Hsieh W-J, Chang H-T, Chen Y-S, Lin T-W, Hsu H-S (2010) Coexpression of Oct4 and nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Can Res 70(24):10433–10444. https://doi.org/10.1158/0008-5472.CAN-10-2638
Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY, Kleeberger SR (2002) Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 26(2):175–182. https://doi.org/10.1165/ajrcmb.26.2.4501
Cho JM, Manandhar S, Lee HR, Park HM, Kwak MK (2008) Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett 260(1–2):96–108. https://doi.org/10.1016/j.canlet.2007.10.022
Choi B-H, Kwak M-K (2016) Shadows of NRF2 in cancer: resistance to chemotherapy. Curr Opin Toxicol 1:20–28. https://doi.org/10.1016/j.cotox.2016.08.003
Choi EJ, Jeon SM (2020) NRF2-driven redox metabolism takes center stage in cancer metabolism from an outside-in perspective. Arch Pharmacal Res 43(3):321–336. https://doi.org/10.1007/s12272-020-01224-3
Choi BH, Ryoo IG, Kang HC, Kwak MK (2014) The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing. PLoS ONE 9(9):e107158. https://doi.org/10.1371/journal.pone.0107158
Choi BH, Ryu DY, Ryoo IG, Kwak MK (2017) NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells. Oncotarget 8(63):107188–107205. https://doi.org/10.18632/oncotarget.22513
Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A, Hayes JD (2013) Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32(32):3765–3781. https://doi.org/10.1038/onc.2012.388
Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousin SP, Rumsey WL, Attucks OC, Franklin S, Levonen AL, Kensler TW, Dinkova-Kostova AT (2019) Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov 18(4):295–317. https://doi.org/10.1038/s41573-018-0008-x
DeBerardinis RJ, Chandel NS (2016) Fundamentals of cancer metabolism. Sci Adv 2(5):e1600200. https://doi.org/10.1126/sciadv.1600200
DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7(1):11–20. https://doi.org/10.1016/j.cmet.2007.10.002
Del Vecchio CA, Feng Y, Sokol ES, Tillman EJ, Sanduja S, Reinhardt F, Gupta PB (2014) De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling. PLoS Biol 12(9):e1001945. https://doi.org/10.1371/journal.pbio.1001945
DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, Tang H, Xie Y, Asara JM, Huffman KE, Wistuba II, Minna JD, DeBerardinis RJ, Cantley LC (2015) NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet 47(12):1475–1481. https://doi.org/10.1038/ng.3421
DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Kenneth HY, Yeo CJ, Calhoun ES (2011a) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475(7354):106–109. https://doi.org/10.1038/nature10189
DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA (2011b) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475(7354):106–109. https://doi.org/10.1038/nature10189
Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239):780–783. https://doi.org/10.1038/nature07733
Do MT, Kim HG, Khanal T, Choi JH, Kim DH, Jeong TC, Jeong HG (2013) Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways. Toxicol Appl Pharmacol 271(2):229–238. https://doi.org/10.1016/j.taap.2013.05.010
Do MT, Kim HG, Choi JH, Jeong HG (2014) Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free Radical Biol Med 74:21–34. https://doi.org/10.1016/j.freeradbiomed.2014.06.010
Duarte TL, Talbot NP, Drakesmith H (2020) NRF2 and hypoxia-inducible factors: key players in the redox control of systemic iron homeostasis. Antioxid Redox Signal. https://doi.org/10.1089/ars.2020.8148
Eales KL, Hollinshead KE, Tennant DA (2016) Hypoxia and metabolic adaptation of cancer cells. Oncogenesis 5(1):e190. https://doi.org/10.1038/oncsis.2015.50
Emmink BL, Verheem A, Van Houdt WJ, Steller EJ, Govaert KM, Pham TV, Piersma SR, Rinkes IHB, Jimenez CR, Kranenburg O (2013) The secretome of colon cancer stem cells contains drug-metabolizing enzymes. J Proteomics 91:84–96. https://doi.org/10.1016/j.jprot.2013.06.027
Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O’Connor T, Harada T, Yamamoto M (2001) High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 59(1):169–177. https://doi.org/10.1093/toxsci/59.1.169
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria RJ (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15(3):504. https://doi.org/10.1038/sj.cdd.4402283
Fabrizio FP, Costantini M, Copetti M, la Torre A, Sparaneo A, Fontana A, Poeta L, Gallucci M, Sentinelli S, Graziano P, Parente P, Pompeo V, De Salvo L, Simone G, Papalia R, Picardo F, Balsamo T, Flammia GP, Trombetta D, Pantalone A, Kok K, Paranita F, Muscarella LA, Fazio VM (2017) Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. Oncotarget 8(7):11187–11198. https://doi.org/10.18632/oncotarget.14492
Farnie G, Clarke RB (2007) Mammary stem cells and breast cancer—role of Notch signalling. Stem Cell Rev 3(2):169–175. https://doi.org/10.1007/s12015-007-0023-5
Fouzder C, Mukhuty A, Mukherjee S, Malick C, Kundu R (2021) Trigonelline inhibits Nrf2 via EGFR signalling pathway and augments efficacy of Cisplatin and Etoposide in NSCLC cells. Toxicol In Vitro 70:105038. https://doi.org/10.1016/j.tiv.2020.105038
Fox DB, Garcia NMG, McKinney BJ, Lupo R, Noteware LC, Newcomb R, Liu J, Locasale JW, Hirschey MD, Alvarez JV (2020) NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism. Nat Metab 2(4):318–334. https://doi.org/10.1038/s42255-020-0191-z
Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, Micaroni M, Chaneton B, Adam J, Hedley A, Kalna G, Tomlinson IP, Pollard PJ, Watson DG, Deberardinis RJ, Shlomi T, Ruppin E, Gottlieb E (2011) Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477(7363):225–228. https://doi.org/10.1038/nature10363
Frohlich DA, McCabe MT, Arnold RS, Day ML (2008) The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene 27(31):4353–4362. https://doi.org/10.1038/onc.2008.79
Gambari L, Lisignoli G, Cattini L, Manferdini C, Facchini A, Grassi F (2014) Sodium hydrosulfide inhibits the differentiation of osteoclast progenitor cells via NRF2-dependent mechanism. Pharmacol Res 87:99–112. https://doi.org/10.1016/j.phrs.2014.06.014
Gao AM, Ke ZP, Shi F, Sun GC, Chen H (2013) Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem Biol Interact 206(1):100–108. https://doi.org/10.1016/j.cbi.2013.08.008
Ghaffari S (2008) Oxidative stress in the regulation of normal and neoplastic hematopoiesis. Antioxid Redox Signal 10(11):1923–1940. https://doi.org/10.1089/ars.2008.2142
Giangreco A, Shen H, Reynolds SD, Stripp BR (2004) Molecular phenotype of airway side population cells. Cell Mol Physiol 286(4):L624–L630. https://doi.org/10.1152/ajplung.00149.2003
Goldstein LD, Lee J, Gnad F, Klijn C, Schaub A, Reeder J, Daemen A, Bakalarski CE, Holcomb T, Shames DS, Hartmaier RJ, Chmielecki J, Seshagiri S, Gentleman R, Stokoe D (2016) Recurrent loss of NFE2L2 exon 2 is a mechanism for Nrf2 pathway activation in human cancers. Cell Rep 16(10):2605–2617. https://doi.org/10.1016/j.celrep.2016.08.010
Gonzalez-Sanchez E, Marin JJ, Perez MJ (2014) The expression of genes involved in hepatocellular carcinoma chemoresistance is affected by mitochondrial genome depletion. Mol Pharm 11(6):1856–1868. https://doi.org/10.1021/mp400732p
Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183(4):1797–1806. https://doi.org/10.1084/jem.183.4.1797
Goto S, Kawabata T, Li TS (2020) Enhanced expression of ABCB1 and Nrf2 in CD133-positive cancer stem cells associates with doxorubicin resistance. Stem Cells Int 2020:8868849. https://doi.org/10.1155/2020/8868849
Greenburg G, Hay ED (1982) Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 95(1):333–339. https://doi.org/10.1083/jcb.95.1.333
Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ESJC (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146(4):633–644. https://doi.org/10.1016/j.cell.2011.07.026
Hadnagy A, Gaboury L, Beaulieu R, Balicki D (2006) SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 312(19):3701–3710. https://doi.org/10.1016/j.yexcr.2006.08.030
Harder B, Tian W, La Clair JJ, Tan AC, Ooi A, Chapman E, Zhang DD (2017) Brusatol overcomes chemoresistance through inhibition of protein translation. Mol Carcinog 56(5):1493–1500. https://doi.org/10.1002/mc.22609
Hayashi A, Suzuki H, Itoh K, Yamamoto M, Sugiyama Y (2003) Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein1 in mouse embryo fibroblasts. Biochem Biophys Res Commun 310(3):824–829. https://doi.org/10.1016/j.bbrc.2003.09.086
Hayes JD, Dinkova-Kostova AT (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39(4):199–218. https://doi.org/10.1016/j.tibs.2014.02.002
Hayes JD, McMahon M (2009) NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34(4):176–188. https://doi.org/10.1016/j.tibs.2008.12.008
Herault O, Hope KJ, Deneault E, Mayotte N, Chagraoui J, Wilhelm BT, Cellot S, Sauvageau M, Andrade-Navarro MA, Hebert J, Sauvageau G (2012) A role for GPx3 in activity of normal and leukemia stem cells. J Exp Med 209(5):895–901. https://doi.org/10.1084/jem.20102386
Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen CJC (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3):313–323. https://doi.org/10.1016/j.stem.2007.06.002
Ho MM, Ng AV, Lam S, Hung JY (2007) Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67(10):4827–4833. https://doi.org/10.1158/0008-5472.CAN-06-3557
Hochmuth CE, Biteau B, Bohmann D, Jasper H (2011) Redox regulation by Keap1 and Nrf2 controls intestinal stem cell proliferation in Drosophila. Cell Stem Cell 8(2):188–199. https://doi.org/10.1016/j.stem.2010.12.006
Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T, Hoshii T, Hirao A, Takagi K, Mizushima T, Motohashi H, Lee MS, Yoshimori T, Tanaka K, Yamamoto M, Komatsu M (2013) Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 51(5):618–631. https://doi.org/10.1016/j.molcel.2013.08.003
Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O, Watanabe S, Ando J, Iwadate M, Yamamoto M, Lee MS, Tanaka K, Komatsu M (2011) Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol 193(2):275–284. https://doi.org/10.1083/jcb.201102031
Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S, Watanabe M, Sakurada A, Endo C, Uruno A, Sasano H, Nakagawa T, Satoh K, Tanaka N, Kubo H, Motohashi H, Yamamoto M (2012) Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci 103(4):760–766. https://doi.org/10.1111/j.1349-7006.2012.02216.x
Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19(3):387–400. https://doi.org/10.1016/j.ccr.2011.01.038
Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, Nomiyama K, Hosokawa K, Sakurada K, Nakagata N, Ikeda Y, Mak TW, Suda T (2004) Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 431(7011):997–1002. https://doi.org/10.1038/nature02989
Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236(2):313–322. https://doi.org/10.1006/bbrc.1997.6943
Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13(1):76–86. https://doi.org/10.1101/gad.13.1.76
Jang YY, Sharkis SJ (2007) A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 110(8):3056–3063. https://doi.org/10.1182/blood-2007-05-087759
Jang J, Wang Y, Kim HS, Lalli MA, Kosik KS (2014) Nrf2, a regulator of the proteasome, controls self-renewal and pluripotency in human embryonic stem cells. Stem Cells 32(10):2616–2625. https://doi.org/10.1002/stem.1764
Jeong H-S, Ryoo I-G, Kwak M-K (2015) Regulation of the expression of renal drug transporters in KEAP1-knockdown human tubular cells. Toxicol In Vitro 29(5):884–892. https://doi.org/10.1016/j.tiv.2015.03.013
Ji X, Wang H, Zhu J, Zhu L, Pan H, Li W, Zhou Y, Cong Z, Yan F, Chen S (2014) Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Int J Cancer 135(3):574–584. https://doi.org/10.1002/ijc.28699
Jia Y, Chen J, Zhu H, Jia Z-H, Cui M-HJ (2015) Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem cell survival via enhanced transcriptional regulation of ABCG2 and Bcl-2/Bmi-1 genes. Oncol Rep 34(5):2296–2304. https://doi.org/10.3892/or.2015.4214
Kakehashi A, Ishii N, Sugihara E, Gi M, Saya H, Wanibuchi H (2016) CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma. Cancer Sci 107(5):609–618. https://doi.org/10.1111/cas.12908
Kalluri R (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Investig 119(6):1417–1419. https://doi.org/10.1172/jci39675
Karathedath S, Rajamani BM, Musheer Aalam SM, Abraham A, Varatharajan S, Krishnamurthy P, Mathews V, Velayudhan SR, Balasubramanian P (2017) Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. PLoS ONE 12(5):e0177227. https://doi.org/10.1371/journal.pone.0177227
Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, Lee KY, Jeong HG, Kang KW (2008) Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med 45(4):537–546. https://doi.org/10.1016/j.freeradbiomed.2008.05.011
Kim T-H, Hur E-g, Kang S-J, Kim J-A, Thapa D, Lee YM, Ku SK, Jung Y, Kwak M-K (2011) NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Can Res 71(6):2260–2275. https://doi.org/10.1158/0008-5472.CAN-10-3007
Kim D, Choi BH, Ryoo IG, Kwak MK (2018) High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling. Cell Death Dis 9(9):896. https://doi.org/10.1038/s41419-018-0903-4
Kim DH, Jang JH, Kwon OS, Cha HJ, Youn HJ, Chun KS, Surh YJ (2020) Nuclear factor erythroid-derived 2-like 2-induced reductive stress favors self-renewal of breast cancer stem-like cells via the FoxO3a-Bmi-1 Axis. Antioxid Redox Signal 32(18):1313–1329. https://doi.org/10.1089/ars.2019.7730
Kitamura H, Motohashi H (2018) NRF2 addiction in cancer cells. Cancer Sci 109(4):900–911. https://doi.org/10.1111/cas.13537
Kitamura H, Onodera Y, Murakami S, Suzuki T, Motohashi H (2017) IL-11 contribution to tumorigenesis in an NRF2 addiction cancer model. Oncogene 36(45):6315–6324. https://doi.org/10.1038/onc.2017.236
Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Hayashi M, Sekine H, Tanaka N, Moriguchi T, Motohashi H, Nakayama K, Yamamoto M (2016) Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun 7:11624. https://doi.org/10.1038/ncomms11624
Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, Motohashi H, Tanaka K, Yamamoto M (2010) The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 12(3):213–223. https://doi.org/10.1038/ncb2021
Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC (2017) KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. eLife 6:18970. https://doi.org/10.7554/eLife.18970
Kwak MK, Egner PA, Dolan PM, Ramos-Gomez M, Groopman JD, Itoh K, Yamamoto M, Kensler TW (2001) Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat Res 480–481:305–315. https://doi.org/10.1016/s0027-5107(01)00190-7
Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW (2003) Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 278(10):8135–8145. https://doi.org/10.1074/jbc.M211898200
Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk FJ (2012) Radiation-induced reprogramming of breast cancer cells. Stem Cells 30(5):833–844. https://doi.org/10.1002/stem.1058
Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O’Dwyer KM (2013) BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12(3):329–341. https://doi.org/10.1016/j.stem.2012.12.013
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JEJN (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645. https://doi.org/10.1038/367645a0
LeBoeuf SE, Wu WL, Karakousi TR, Karadal B, Jackson SR, Davidson SM, Wong KK, Koralov SB, Sayin VI, Papagiannakopoulos T (2020) Activation of oxidative stress response in cancer generates a druggable dependency on exogenous non-essential amino acids. Cell Metab 31(2):339-350.e334. https://doi.org/10.1016/j.cmet.2019.11.012
Lee S, Hallis SP, Jung KA, Ryu D, Kwak MK (2019) Impairment of HIF-1α-mediated metabolic adaption by NRF2-silencing in breast cancer cells. Redox Biol 24:101210. https://doi.org/10.1016/j.redox.2019.101210
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007) Identification of pancreatic cancer stem cells. Cancer Res 67(3):1030–1037. https://doi.org/10.1158/0008-5472.CAN-06-2030
Lien EC, Lyssiotis CA, Juvekar A, Hu H, Asara JM, Cantley LC, Toker A (2016) Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. Nat Cell Biol 18(5):572–578. https://doi.org/10.1038/ncb3341
Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M, Karakousi TR, Pass HI, Bhutkar AJ, Tsirigos A, Ueberheide B, Sayin VI, Papagiannakopoulos T, Pagano M (2019) Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1. Cell 178(2):316-329.e318. https://doi.org/10.1016/j.cell.2019.06.003
Loignon M, Miao W, Hu L, Bier A, Bismar TA, Scrivens PJ, Mann K, Basik M, Bouchard A, Fiset PO, Batist Z, Batist G (2009) Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Mol Cancer Ther 8(8):2432–2440. https://doi.org/10.1158/1535-7163.Mct-08-1186
Luo J, Manning BD, Cantley LC (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4(4):257–262. https://doi.org/10.1016/s1535-6108(03)00248-4
Luo M, Shang L, Brooks MD, Jiagge E, Zhu Y, Buschhaus JM, Conley S, Fath MA, Davis A, Gheordunescu E, Wang Y, Harouaka R, Lozier A, Triner D, McDermott S, Merajver SD, Luker GD, Spitz DR, Wicha MS (2018) Targeting breast cancer stem cell state equilibrium through modulation of redox signaling. Cell Metab 28(1):69-86.e66. https://doi.org/10.1016/j.cmet.2018.06.006
Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happel C, Shyr C, Wakabayashi N, Kensler TW, Wasserman WW, Biswal S (2010) Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 38(17):5718–5734. https://doi.org/10.1093/nar/gkq212
Meng D, Wang X, Chang Q, Hitron A, Zhang Z, Xu M, Chen G, Luo J, Jiang B, Fang J, Shi X (2010) Arsenic promotes angiogenesis in vitro via a heme oxygenase-1-dependent mechanism. Toxicol Appl Pharmacol 244(3):291–299. https://doi.org/10.1016/j.taap.2010.01.004
Merchant AA, Singh A, Matsui W, Biswal S (2011) The redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels. Blood 118(25):6572–6579. https://doi.org/10.1182/blood-2011-05-355362
Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H (2012) Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22(1):66–79. https://doi.org/10.1016/j.ccr.2012.05.016
Mizuno T, Suzuki N, Makino H, Furui T, Morii E, Aoki H, Kunisada T, Morishige K (2014) Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species. Gynecol Oncol 137(2):299–305. https://doi.org/10.1016/j.ygyno.2014.12.005
Mogi M, Yang J, Lambert JF, Colvin GA, Shiojima I, Skurk C, Summer R, Fine A, Quesenberry PJ, Walsh K (2003) Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 278(40):39068–39075. https://doi.org/10.1074/jbc.M306362200
Morita K, Lee MS, Her S (2009) Possible relation of hemin-induced HO-1 expression to the upregulation of VEGF and BDNF mRNA levels in rat C6 glioma cells. J Mol Neurosci 38(1):31–40. https://doi.org/10.1007/s12031-008-9156-5
Mukhopadhyay S, Goswami D, Adiseshaiah PP, Burgan W, Yi M, Guerin TM, Kozlov SV, Nissley DV, McCormick F (2020) Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers. Can Res 80(8):1630–1643. https://doi.org/10.1158/0008-5472.Can-19-1363
Murakami S, Motohashi H (2015) Roles of Nrf2 in cell proliferation and differentiation. Free Radic Biol Med 88(Pt B):168–178. https://doi.org/10.1016/j.freeradbiomed.2015.06.030
Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, Nakao S, Motoyama N, Hirao A (2010) TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 463(7281):676–680. https://doi.org/10.1038/nature08734
Network CGAR (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519–525. https://doi.org/10.1038/nature11404
Network CGAR (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543–550. https://doi.org/10.1038/nature13385
O’Brien CA, Pollett A, Gallinger S, Dick JEJN (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106. https://doi.org/10.1038/nature05372
Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T, Shibata T, Yamamoto M, Hirohashi S (2008) Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Can Res 68(5):1303–1309. https://doi.org/10.1158/0008-5472.Can-07-5003
Otsuki A, Yamamoto M (2020) Cis-element architecture of Nrf2-sMaf heterodimer binding sites and its relation to diseases. Arch Pharmacal Res 43(3):275–285. https://doi.org/10.1007/s12272-019-01193-2
Owusu-Ansah E, Banerjee U (2009) Reactive oxygen species prime Drosophila haematopoietic progenitors for differentiation. Nature 461(7263):537–541. https://doi.org/10.1038/nature08313
Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S, Yamamoto M (2006) Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21(5):689–700. https://doi.org/10.1016/j.molcel.2006.01.013
Panieri E, Buha A, Telkoparan-Akillilar P, Cevik D, Kouretas D, Veskoukis A, Skaperda Z, Tsatsakis A, Wallace D, Suzen S, Saso L (2020) Potential applications of NRF2 modulators in cancer therapy. Antioxidants 9(3):193. https://doi.org/10.3390/antiox9030193
Paul MK, Bisht B, Darmawan DO, Chiou R, Ha VL, Wallace WD, Chon AT, Hegab AE, Grogan T, Elashoff DA (2014) Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis through Nrf2-dependent notch signaling. Cell Stem Cell 15(2):199–214. https://doi.org/10.1016/j.stem.2014.05.009
Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98(24):1777–1785. https://doi.org/10.1093/jnci/djj495
Pierce G, Cox WJ (1978) Neoplasms as caricatures of tissue renewal. In: Cell differentiation and neoplasia, pp 57–66
Pierce GB, Speers WC (1988) Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 48(8):1996–2004
Rachakonda G, Sekhar KR, Jowhar D, Samson PC, Wikswo JP, Beauchamp RD, Datta PK, Freeman ML (2010) Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene 29(25):3703–3714. https://doi.org/10.1038/onc.2010.118
Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cuadrado A (2011) SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol 31(6):1121–1133. https://doi.org/10.1128/mcb.01204-10
Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98(6):3410–3415. https://doi.org/10.1073/pnas.051618798
Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, Yamamoto M, Petrache I, Tuder RM, Biswal S (2004) Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Investig 114(9):1248–1259. https://doi.org/10.1172/jci21146
Reddy NM, Kleeberger SR, Cho HY, Yamamoto M, Kensler TW, Biswal S, Reddy SP (2007) Deficiency in Nrf2-GSH signaling impairs type II cell growth and enhances sensitivity to oxidants. Am J Respir Cell Mol Biol 37(1):3–8. https://doi.org/10.1165/rcmb.2007-0004RC
Reddy NM, Kleeberger SR, Bream JH, Fallon PG, Kensler TW, Yamamoto M, Reddy SP (2008) Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. Oncogene 27(44):5821–5832. https://doi.org/10.1038/onc.2008.188
Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, Zhang DD (2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci USA 108(4):1433–1438. https://doi.org/10.1073/pnas.1014275108
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria RJN (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123):111. https://doi.org/10.1038/nature05384
Rojo de la Vega M, Chapman E, Zhang DD (2018) NRF2 and the hallmarks of cancer. Cancer Cell. https://doi.org/10.1016/j.ccell.2018.03.022
Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sánchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, Thomas CJ, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, Papagiannakopoulos T (2017) Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med 23(11):1362–1368. https://doi.org/10.1038/nm.4407
Ryoo I, Choi B, Kwak M (2015) Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells. Oncotarget 6(10):8167–8184. https://doi.org/10.18632/oncotarget.3047
Ryoo IG, Kim G, Choi BH, Lee SH, Kwak MK (2016a) Involvement of NRF2 signaling in doxorubicin resistance of cancer stem cell-enriched colonospheres. Biomol Ther 24(5):482–488. https://doi.org/10.4062/biomolther.2016.145
Ryoo IG, Lee SH, Kwak MK (2016b) Redox modulating NRF2: a potential mediator of cancer stem cell resistance. Oxid Med Cell Longev 2016:2428153. https://doi.org/10.1155/2016/2428153
Ryoo IG, Choi BH, Ku SK, Kwak MK (2018) High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: Implications for cancer stem cell resistance. Redox Biol 17:246–258. https://doi.org/10.1016/j.redox.2018.04.015
Ryu D, Lee JH, Kwak MK (2020) NRF2 level is negatively correlated with TGF-β1-induced lung cancer motility and migration via NOX4-ROS signaling. Arch Pharmacal Res 43(12):1297–1310. https://doi.org/10.1007/s12272-020-01298-z
Saito T, Ichimura Y, Taguchi K, Suzuki T, Mizushima T, Takagi K, Hirose Y, Nagahashi M, Iso T, Fukutomi T, Ohishi M, Endo K, Uemura T, Nishito Y, Okuda S, Obata M, Kouno T, Imamura R, Tada Y, Obata R, Yasuda D, Takahashi K, Fujimura T, Pi J, Lee MS (2016) p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat Commun 7:12030. https://doi.org/10.1038/ncomms12030
Salmina K, Jankevics E, Huna A, Perminov D, Radovica I, Klymenko T, Ivanov A, Jascenko E, Scherthan H, Cragg MJ (2010) Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. Exp Cell Res 316(13):2099–2112. https://doi.org/10.1016/j.yexcr.2010.04.030
Saretzki G, Armstrong L, Leake A, Lako M, von Zglinicki T (2004) Stress defense in murine embryonic stem cells is superior to that of various differentiated murine cells. Stem Cells 22(6):962–971. https://doi.org/10.1634/stemcells.22-6-962
Satoh H, Moriguchi T, Takai J, Ebina M, Yamamoto M (2013) Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Can Res 73(13):4158–4168. https://doi.org/10.1158/0008-5472.CAN-12-4499
Sayin VI, LeBoeuf SE, Singh SX, Davidson SM, Biancur D, Guzelhan BS, Alvarez SW, Wu WL, Karakousi TR, Zavitsanou AM, Ubriaco J, Muir A, Karagiannis D, Morris PJ, Thomas CJ, Possemato R, Vander Heiden MG, Papagiannakopoulos T (2017) Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. eLife 6:28083. https://doi.org/10.7554/eLife.28083
Schmidlin CJ, Dodson MB, Zhang DD (2020) Filtering through the role of NRF2 in kidney disease. Arch Pharmacal Res 43(3):361–369. https://doi.org/10.1007/s12272-019-01177-2
Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Göktuna SI, Ziegler PK, Canli O, Heijmans J, Huels DJ, Moreaux GJC (2013) Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152(1):25–38. https://doi.org/10.1016/j.cell.2012.12.012
Shen H, Yang Y, Xia S, Rao B, Zhang J, Wang J (2014) Blockage of Nrf2 suppresses the migration and invasion of esophageal squamous cell carcinoma cells in hypoxic microenvironment. Dis Esophagus 27(7):685–692. https://doi.org/10.1111/dote.12124
Shen X, Zhao Y, Liu G, Zhou HL, Fan J, Zhang L, Li YL, Wang Y, Liang J, Xu ZX (2020) Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer. Life Sci 256:117923. https://doi.org/10.1016/j.lfs.2020.117923
Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, Yoshimatsu Y, Tachimori Y, Kushima R, Kiyono T, Yamamoto M (2011) NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 13(9):864–873. https://doi.org/10.1593/neo.11750
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396. https://doi.org/10.1038/nature03128
Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E (2006a) Dysfunctional KEAP1–NRF2 interaction in non-small-cell lung cancer. PLoS Med 3(10):e420. https://doi.org/10.1371/journal.pmed.0030420
Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV, Biswal S (2006b) Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3(10):e420. https://doi.org/10.1371/journal.pmed.0030420
Singh A, Wu H, Zhang P, Happel C, Ma J, Biswal S (2010) Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther 9(8):2365–2376. https://doi.org/10.1158/1535-7163.MCT-10-0108
Singh A, Daemen A, Nickles D, Jeon SM, Foreman O, Sudini K, Gnad F, Lajoie S, Gour N, Mitzner W, Chatterjee S, Choi EJ, Ravishankar B, Rappaport A, Patil N, McCleland M, Johnson L, Acquaah-Mensah G, Gabrielson E, Biswal S, Hatzivassiliou G (2020) NRF2 Activation promotes aggressive lung cancer and associates with poor clinical outcomes. Clin Cancer Res. https://doi.org/10.1158/1078-0432.Ccr-20-1985
Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ, Wistuba II (2010) Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16(14):3743–3753. https://doi.org/10.1158/1078-0432.ccr-09-3352
Sun X, Wang Q, Wang Y, Du L, Xu C, Liu Q (2016) Brusatol enhances the radiosensitivity of A549 cells by promoting ros production and enhancing DNA damage. Int J Mol Sci 17(7):997. https://doi.org/10.3390/ijms17070997
Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, Matsuno S, Shibahara S, Abraham NG (2003) Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 6(1):15–24. https://doi.org/10.1023/a:1025803600840
Taguchi K, Kensler TW (2020) Nrf2 in liver toxicology. Arch Pharmacal Res 43(3):337–349. https://doi.org/10.1007/s12272-019-01192-3
Tang X, Wang H, Fan L, Wu X, Xin A, Ren H, Wang XJ (2011) Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med 50(11):1599–1609. https://doi.org/10.1016/j.freeradbiomed.2011.03.008
Taniguchi S, Elhance A, Van Duzer A, Kumar S, Leitenberger JJ, Oshimori N (2020) Tumor-initiating cells establish an IL-33-TGF-β niche signaling loop to promote cancer progression. Science 369(6501):1813. https://doi.org/10.1126/science.aay1813
Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK, Zhang DD (2014) Oncogenic KRAS confers chemoresistance by upregulating NRF2. Can Res 74(24):7430–7441. https://doi.org/10.1158/0008-5472
Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, Hayes JD (2015) Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med 88(Pt B):108–146. https://doi.org/10.1016/j.freeradbiomed.2015.06.021
Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S (2002) Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Can Res 62(18):5196–5203
Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegue E, DePinho RA, Gilliland DG (2007) FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128(2):325–339. https://doi.org/10.1016/j.cell.2007.01.003
Tsai JJ, Dudakov JA, Takahashi K, Shieh J-H, Velardi E, Holland AM, Singer NV, West ML, Smith OM, Young LF (2013) Nrf2 regulates haematopoietic stem cell function. Nat Cell Biol 15(3):309–316. https://doi.org/10.1038/ncb2699
Tsuchida K, Tsujita T, Hayashi M, Ojima A, Keleku-Lukwete N, Katsuoka F, Otsuki A, Kikuchi H, Oshima Y, Suzuki M, Yamamoto M (2017) Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radic Biol Med 103:236–247. https://doi.org/10.1016/j.freeradbiomed.2016.12.041
Tu W, Wang H, Li S, Liu Q, Sha H (2019) The anti-inflammatory and anti-oxidant mechanisms of the keap1/Nrf2/ARE signaling pathway in chronic diseases. Aging Dis 10(3):637–651. https://doi.org/10.14336/ad.2018.0513
Tung MC, Lin PL, Wang YC, He TY, Lee MC, Yeh SD, Chen CY, Lee H (2015) Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2. Oncotarget 6(39):41692–41705. https://doi.org/10.18632/oncotarget.6150
Umemura A, He F, Taniguchi K, Nakagawa H, Yamachika S, Font-Burgada J, Zhong Z, Subramaniam S, Raghunandan S, Duran A, Linares JF, Reina-Campos M, Umemura S, Valasek MA, Seki E, Yamaguchi K, Koike K, Itoh Y, Diaz-Meco MT, Moscat J, Karin M (2016) p62, Upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. Cancer Cell 29(6):935–948. https://doi.org/10.1016/j.ccell.2016.04.006
Valenzuela M, Glorieux C, Stockis J, Sid B, Sandoval JM, Felipe KB, Kviecinski MR, Verrax J, Buc Calderon P (2014) Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. Br J Cancer 111(5):874–882. https://doi.org/10.1038/bjc.2014.380
Vermeulen L, Felipe De Sousa EM, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12(5):468–476. https://doi.org/10.1038/ncb2048
Wakabayashi N, Shin S, Slocum SL, Agoston ES, Wakabayashi J, Kwak M-K, Misra V, Biswal S, Yamamoto M, Kensler TW (2010) Regulation of notch1 signaling by nrf2: implications for tissue regeneration. Sci Signal 3(130):ra52. https://doi.org/10.1126/scisignal.2000762
Wang XJ, Hayes JD, Henderson CJ, Wolf CR (2007) Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc Natl Acad Sci USA 104(49):19589–19594. https://doi.org/10.1073/pnas.0709483104
Wang R, An J, Ji F, Jiao H, Sun H, Zhou D (2008) Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 373(1):151–154. https://doi.org/10.1016/j.bbrc.2008.06.004
Wang K, Zhang T, Dong Q, Nice EC, Huang C, Wei Y (2013) Redox homeostasis: the linchpin in stem cell self-renewal and differentiation. Cell Death Dis 4:e537. https://doi.org/10.1038/cddis.2013.50
Wang X, Campos CR, Peart JC, Smith LK, Boni JL, Cannon RE, Miller DS (2014) Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood–brain and blood–spinal cord barriers. J Neurosci 34(25):8585–8593. https://doi.org/10.1523/JNEUROSCI.2935-13.2014
Wu S, Lu H, Bai Y (2019) Nrf2 in cancers: A double-edged sword. Cancer Med 8(5):2252–2267. https://doi.org/10.1002/cam4.2101
Wu T, Harder BG, Wong PK, Lang JE, Zhang DD (2014) Oxidative stress, mammospheres and Nrf2–new implication for breast cancer therapy? Mol Carcinog 54(11):1494–1502. https://doi.org/10.1002/mc.22202
Yamadori T, Ishii Y, Homma S, Morishima Y, Kurishima K, Itoh K, Yamamoto M, Minami Y, Noguchi M, Hizawa N (2012) Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene 31(45):4768–4777. https://doi.org/10.1038/onc.2011.628
Yamamoto M, Kensler TW, Motohashi H (2018) The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiol Rev 98(3):1169–1203. https://doi.org/10.1152/physrev.00023.2017
Yasuda D, Ohe T, Takahashi K, Imamura R, Kojima H, Okabe T, Ichimura Y, Komatsu M, Yamamoto M, Nagano T, Mashino T (2020) Inhibitors of the protein-protein interaction between phosphorylated p62 and Keap1 attenuate chemoresistance in a human hepatocellular carcinoma cell line. Free Radic Res. https://doi.org/10.1080/10715762.2020.1732955
Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441(7092):475–482. https://doi.org/10.1038/nature04703
Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, Mukai M, Asoda S, Kawana H, Nakagawa T, Saya H, Nagano O (2013) xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Can Res 73(6):1855–1866. https://doi.org/10.1158/0008-5472.can-12-3609-t
Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H, Ai W (2011) Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 30(18):2161–2172. https://doi.org/10.1038/onc.2010.591
Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG, Biswal S (2010) Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 9(2):336–346. https://doi.org/10.1158/1535-7163.Mct-09-0589
Zhang C, Wang HJ, Bao QC, Wang L, Guo TK, Chen WL, Xu LL, Zhou HS, Bian JL, Yang YR, Sun HP, Xu XL, You QD (2016) NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction. Oncotarget 7(45):73593–73606. https://doi.org/10.18632/oncotarget.12435
Zhang D, Rennhack J, Andrechek ER, Rockwell CE, Liby KT (2018a) Identification of an unfavorable immune signature in advanced lung tumors from Nrf2-deficient mice. Antioxid Redox Signal 29(16):1535–1552. https://doi.org/10.1089/ars.2017.7201
Zhang J, Jiao K, Liu J, Xia Y (2018b) Metformin reverses the resistance mechanism of lung adenocarcinoma cells that knocks down the Nrf2 gene. Oncol Lett 16(5):6071–6080. https://doi.org/10.3892/ol.2018.9382
Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D (2009) Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458(7239):776–779. https://doi.org/10.1038/nature07737
Zhao Q, Mao A, Guo R, Zhang L, Yan J, Sun C, Tang J, Ye Y, Zhang Y, Zhang H (2017) Suppression of radiation-induced migration of non-small cell lung cancer through inhibition of Nrf2-Notch Axis. Oncotarget 8(22):36603–36613. https://doi.org/10.18632/oncotarget.16622
Zhu J, Thompson CB (2019) Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol 20(7):436–450. https://doi.org/10.1038/s41580-019-0123-5
Zhu J, Wang H, Sun Q, Ji X, Zhu L, Cong Z, Zhou Y, Liu H, Zhou M (2013) Nrf2 is required to maintain the self-renewal of glioma stem cells. BMC Cancer 13(1):380. https://doi.org/10.1186/1471-2407-13-380
Zhu J, Wang H, Fan Y, Hu Y, Ji X, Sun Q, Liu HJ (2014) Knockdown of nuclear factor erythroid 2-related factor 2 by lentivirus induces differentiation of glioma stem-like cells. Oncol Rep 32(3):1170–1178. https://doi.org/10.3892/or.2014.3320
Zhu J, Wang H, Chen F, Fu J, Xu Y, Hou Y, Kou HH, Zhai C, Nelson MB, Zhang Q, Andersen ME, Pi J (2016) An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy. Free Radic Biol Med 99:544–556. https://doi.org/10.1016/j.freeradbiomed.2016.09.010
Zhu B, Tang L, Chen S, Yin C, Peng S, Li X, Liu T, Liu W, Han C, Stawski L, Xu ZX, Zhou G, Chen X, Gao X, Goding CR, Xu N, Cui R, Cao P (2018) Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. Oncogene 37(36):4941–4954. https://doi.org/10.1038/s41388-018-0314-0
Acknowledgements
This study was financially supported by Grants from the National Research Foundation of Korea (NRF) funded by the Korean government (MSIT) (2018R1A2A1A05078894, 2018R1A6A1A03025108). This study was also supported by the BK21FOUR program and the Catholic University of Korea, Research Fund 2019.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Choi, BH., Kim, J.M. & Kwak, MK. The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance. Arch. Pharm. Res. 44, 263–280 (2021). https://doi.org/10.1007/s12272-021-01316-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-021-01316-8